Human Genome Sciences

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Retrieved on:

火曜日, 5月 7, 2024

Ulcerative colitis, FBR, Economics, ImClone Systems, Harvard Business School, Therapy, Patient, Wall, Lehman Brothers, Street, Citigroup, Human Genome Sciences, Drug development, Biomarker, Chase Bank, Harvard University, Autoimmunity, UC, Pharmaceutical industry

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors.

Key Points:

Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive.
“We are excited to welcome Margery to our Board of Directors.
Prior to rejoining the banking industry, Ms. Fischbein held senior corporate positions at ImClone Systems and Human Genome Sciences.
Ms. Fischbein earned a master’s degree in business administration from Harvard Business School and a bachelor’s degree in economics from Harvard University.

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

Retrieved on:

木曜日, 4月 25, 2024

Conditional sentence, Sarilumab, Ulcerative colitis, AbbVie, Research, Roche, Novartis, Patient, Psoriasis, Secukinumab, Morphic, Human Genome Sciences, Drug development, Clinical trial, Therapy, Sanofi, Organization, UC, Pharmaceutical industry

WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter 2024.

Key Points:

-Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027-
WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter 2024.
“Morphic continues to execute our strategy with the EMERALD-2 phase 2b study in ulcerative colitis (UC) recruiting on target, and we are excited to begin enrollment in the GARNET phase 2 study in patients with moderate to severe Crohn’s disease (CD),” commented Praveen Tipirneni, CEO of Morphic Therapeutic.
“We look forward to continued progress both with MORF-057 and our earlier-stage pipeline, including our program in pulmonary hypertensive diseases.
The increase was primarily attributable to increased non-cash stock-based compensation expenses
Based on its current operating plan, Morphic believes its existing cash, cash equivalents and marketable securities as of March 31, 2024, will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2027.

NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

Retrieved on:

火曜日, 4月 2, 2024

Mallinckrodt, Inflammation, Pharmacology, McGill University, Organization, Acute radiation syndrome, ARS, KOSDAQ, Research, EDT, Senior, Doctor of Philosophy, IL-7, Human Genome Sciences, Drug development, Division, NIT, Vertex Pharmaceuticals

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).

Key Points:

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).
Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc.
In his new role, Dr. Oh will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea.
Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech."

Bioforum Expands Leadership Team with Appointment of Michael Goedde as President

Retrieved on:

火曜日, 3月 19, 2024

NESS ZIONA, Israel, March 19, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the appointment of Michael Goedde as its President. A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.

Key Points:

A clinical data management expert whose career in the life sciences industry spans over three decades, Goedde will drive the development and execution of Bioforum's global growth and innovation strategy.
"As we expand our presence in North America and around the world, I'm delighted to welcome Michael to the Bioforum family and confident that his leadership will be invaluable in driving our long-term growth and success."
Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations.
He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in Frankfurt, Germany.

NeoImmuneTech Welcomes a New President for its Development and Business

Retrieved on:

月曜日, 1月 15, 2024

Senior, Research, Human Genome Sciences, Biosimilar, NIT, Pharmacology, McGill University, Division, Drug development, Inflammation, Acute radiation syndrome, Organization, Doctor of Philosophy, IL-7, ARS, Mallinckrodt, Vertex Pharmaceuticals, Pharmaceutical industry

ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.

Key Points:

ROCKVILLE, Md., Jan. 15, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.
Dr. Oh is an expert in regulatory policies and drug development, encompassing both biologics and small molecules.
Se Hwan Yang, Ph.D., Chief Executive Officer of NeoImmuneTech, Inc. said: "We are delighted to welcome Dr. Oh to our team.
His strong expertise and extensive network are invaluable assets that will propel our clinical development program and business activities.

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

Retrieved on:

月曜日, 12月 11, 2023

SPL, Marketing, Lead, Partnership, GSK plc, FDA, Acquisition, Research, Retirement, Molecular biology, University, Genetics, Human Genome Sciences, Therapy, Expert, EVP, Corporate lawyer, Management

ROCKVILLE, Md., Dec. 11, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that Maher Masoud has been named President and Chief Executive Officer of MaxCyte, succeeding Doug Doerfler, who will retire as President and Chief Executive Officer, effective January 1, 2024. Mr. Masoud, currently the Company’s EVP, Head of Global Business Development and Chief Counsel, will also serve as a director on MaxCyte’s Board of Directors. Mr. Doerfler will step down from the Board of Directors upon his retirement and will remain an advisor to the Company.

Key Points:

Mr. Doerfler founded MaxCyte in 1999 and served as CEO for 24 years, leading the Company from initial technology concept through to the commercialization of its flow electroporation technology.
Throughout Doug’s tenure, MaxCyte grew to become the partner of choice to leading cell and gene therapy drug developers."
Mr. Masoud has most recently served as EVP, Head of Global Business Development and Chief Counsel at MaxCyte.
Prior to joining MaxCyte, he oversaw the operations of six business subsidiaries at Wellstat, a life science holding company.

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

Retrieved on:

水曜日, 11月 15, 2023

NEW YORK, Nov. 15, 2023 /PRNewswire-PRWeb/ -- The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Key Points:

The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
"Cancer target discovery research has traditionally concentrated on pinpointing genes that facilitate cancer cell growth and survival.
It allows them to see how cancer genes affect not only cancer cells but also the immune system within tumors.

Mount Sinai Researchers Find More Than 4,700 Gene Clusters Crucial for Prognosis in 32 Cancer Types

Retrieved on:

月曜日, 11月 13, 2023

Doctor of Philosophy, Research, Cancer, Genome Research, TCGA, Human Genome Sciences, The Cancer Genome Atlas, Vaccine, Genetics

NEW YORK, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed "prognostic modules," that significantly influence the progression of 32 different types of cancer.

Key Points:

NEW YORK, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed "prognostic modules," that significantly influence the progression of 32 different types of cancer.
Previous research often focused on isolated gene functions in specific cancer types.
We have identified 4,749 distinct co-regulated gene modules that play a pivotal role in cancer progression," explained Dr. Zhang.
"Our findings offer fertile ground for the next wave of cancer research and treatment strategies," said Dr. Zhang.

The Galien Foundation Honors 2023 Prix Galien Award Recipients

Retrieved on:

金曜日, 10月 27, 2023

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The Prix Galien USA Committees honored excellence and innovation in life sciences during the Prix Galien USA Forum and 17h annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City. The USA Committees, composed of 20 committee members, 12 subcommittee members and 20 advisory board members, represented renowned leaders from the biomedical industry and academia. With three Nobel Laureates, these groups honored this year's award winners in the following categories: "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Product for Rare/Orphan Diseases," "Best Medical Technology," "Best Digital Health Solution," "Incubators, Accelerators and Equity" and "Best Startup."

Key Points:

"We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry," said Bruno Cohen, Chairman of The Galien Foundation.
"Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our gratitude to each winner and nominee, and we look forward to witnessing their impact on the future of global healthcare."
The Prix Galien Awards were created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, to recognize outstanding innovation and scientific advancement.
With chapters in 14 countries and Africa, and an inaugural chapter being established in India in 2024, Prix Galien is regarded worldwide as the equivalent of the Nobel Prize for the life science industry.

Ceremorphic Announces New Life Sciences Division with New Design Methodology Based on its Proprietary Analog and AI Technology that Can Significantly Reduce R&D Costs

Retrieved on:

火曜日, 10月 24, 2023

Ceremorphic’s life sciences division leverages its over 5,000 person-year expertise of hardware, algorithms and AI to make this new architecture a reality.

Key Points:

Ceremorphic’s life sciences division leverages its over 5,000 person-year expertise of hardware, algorithms and AI to make this new architecture a reality.
In alignment with our business model, Ceremorphic Life Sciences envisions developing pharmaceuticals and overseeing the essential clinical trials.
Unlike current in silico methods, Ceremorphic Life Sciences works with its own foundation models generated through its own proprietary relevant data synthesis methods.
Ceremorphic Life Sciences Division is headquartered in San Jose, CA and leverages engineering resources from Ceremorphic’s state-of-the art design center in Hyderabad, India.